Zobrazeno 1 - 10
of 7 427
pro vyhledávání: '"Remberger, M."'
Autor:
Pasic I; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada. Electronic address: ivan.pasic@uhn.ca., Moya TA; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Remberger M; Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden., Chen C; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada., Gerbitz A; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Kim DDH; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Kumar R; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Lam W; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Law AD; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Lipton JH; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Michelis FV; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Novitzky-Basso I; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Viswabandya A; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada., Mattsson J; Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2024 Jul; Vol. 30 (7), pp. 681.e1-681.e11. Date of Electronic Publication: 2024 Apr 20.
Autor:
Grønvold BL; Department of Haematology Oslo University Hospital Oslo Norway.; Institute of Clinical Medicine University of Oslo Oslo Norway., Ali MM; Department of Haematology Oslo University Hospital Oslo Norway., Myklebust TÅ; Department of Registration Cancer Registry Norway Oslo Norway.; Department of Research and Innovation Møre and Romsdal Hospital Trust Ålesund Norway., Lenartova A; Department of Haematology Oslo University Hospital Oslo Norway., Remberger M; Department of Haematology Oslo University Hospital Oslo Norway.; Department of Medical Sciences Uppsala University and KFUE Uppsala University Hospital Uppsala Sweden., Abrahamsen IW; Department of Haematology Oslo University Hospital Oslo Norway., Tjønnfjord GE; Department of Haematology Oslo University Hospital Oslo Norway.; Institute of Clinical Medicine University of Oslo Oslo Norway., Myhre AE; Department of Haematology Oslo University Hospital Oslo Norway., Fløisand Y; Center for Cancer Cell Reprogramming Institute of Clinical Medicine University of Oslo Oslo Norway., Gedde-Dahl T; Department of Haematology Oslo University Hospital Oslo Norway.; Institute of Clinical Medicine University of Oslo Oslo Norway.
Publikováno v:
EJHaem [EJHaem] 2024 Feb 05; Vol. 5 (1), pp. 117-124. Date of Electronic Publication: 2024 Feb 05 (Print Publication: 2024).
Autor:
Pang I; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Chen P; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Trinh GV; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Remberger M; Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden., Novitzky-Basso I; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Gerbitz A; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Kim DD; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Kumar R; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Lam W; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Law AD; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Lipton JH; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Viswabandya A; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Pasic I; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Mattsson J; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Michelis FV; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada.
Publikováno v:
European journal of haematology [Eur J Haematol] 2024 Feb; Vol. 112 (2), pp. 301-309. Date of Electronic Publication: 2023 Oct 13.
Autor:
Garcia-Horton A; Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.; Department of Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada., Cyriac SL; Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.; Department of Medical Oncology and Hematology, Amala Institute of Medical Sciences, Thrissur, India., Gedde-Dahl T; Stem Cell Transplant Unit, Department of Hematology, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Floisand Y; Stem Cell Transplantation and Cellular Therapies Programme, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.; CanCell - Centre of Cancer Cell Reprogramming, University of Oslo, Oslo, Norway., Remberger M; Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden., Mattsson J; Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.; Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada., Michelis FV; Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Publikováno v:
European journal of haematology [Eur J Haematol] 2022 Dec; Vol. 109 (6), pp. 672-679. Date of Electronic Publication: 2022 Sep 10.
Autor:
Pasic, I., Remberger, M., Chen, C., Gerbitz, A., Kim, D., Kumar, R., Lam, W., Law, A., Lipton, J., Michelis, F., Novitzky-Basso, I., Viswabandya, A., Mattsson, J.
Publikováno v:
In Leukemia Research May 2023 128 Supplement
Autor:
Pereira MP; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada., Remberger M; Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden., Chen C; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada., Gerbitz A; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Kim DDH; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Kumar R; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Lam W; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Law AD; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Lipton JH; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Michelis FV; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Novitzky-Basso I; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Viswabandya A; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Mattsson J; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Pasic I; Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: ivan.pasic@uhn.ca.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2023 Nov; Vol. 29 (11), pp. 697.e1-697.e10. Date of Electronic Publication: 2023 Aug 12.
Autor:
Novitzky-Basso I; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Remberger M; Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden., Chen C; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Ellison C; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Pasic I; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Lam W; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Law A; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Gerbitz A; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Viswabandya A; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Lipton JH; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Kim DD; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Kumar R; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Michelis FV; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada., Mattsson J; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.; University of Toronto, Toronto, Canada.; Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, Department of Medicine, University of Toronto, Toronto, Canada.
Publikováno v:
European journal of haematology [Eur J Haematol] 2022 Apr; Vol. 108 (4), pp. 288-297. Date of Electronic Publication: 2021 Dec 27.
Autor:
Gerbitz A; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany.; Princess Margaret Cancer Centre, Division of Medical Oncology/Hematology, Toronto, ON, Canada., Gary R; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Aigner M; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Moosmann A; Department of Medicine 3, LMU University Hospital, Munich, Germany.; Helmholtz Center Munich, Institute of Virology, Munich, Germany.; Deutsches Zentrum für Infektionsforschung (DZIF) - German Center for Infection Research, Munich, Germany., Kremer A; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Schmid C; Department of Medicine 2, University Hospital Augsburg, Augsburg, Germany., Hirschbuehl K; Department of Medicine 2, University Hospital Augsburg, Augsburg, Germany., Wagner E; Department of Medicine 3, University Hospital Mainz, Mainz, Germany., Hauptrock B; Department of Medicine 3, University Hospital Mainz, Mainz, Germany., Teschner D; Department of Medicine 3, University Hospital Mainz, Mainz, Germany., Roesler W; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Spriewald B; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Tischer J; Department of Medicine 3, LMU University Hospital, Munich, Germany., Moi S; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Balzer H; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Schaffer S; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Bausenwein J; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Wagner A; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Schmidt F; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany., Brestrich J; Department of Hematology, Oncology and Tumor Immunology, Charite University Hospital Berlin, Berlin, Germany., Ullrich B; Medical Center for Information and Communication Technology, University Hospital Erlangen, Erlangen, Germany., Maas S; Center for Clinical Studies (CCS), University Hospital Erlangen, Erlangen, Germany., Herold S; Center for Clinical Studies (CCS), University Hospital Erlangen, Erlangen, Germany., Strobel J; Department of Transfusion Medicine, University Hospital Erlangen, Erlangen, Germany., Zimmermann R; Department of Transfusion Medicine, University Hospital Erlangen, Erlangen, Germany., Weisbach V; Department of Transfusion Medicine, University Hospital Erlangen, Erlangen, Germany., Hansmann L; Department of Hematology, Oncology and Tumor Immunology, Charite University Hospital Berlin, Berlin, Germany., Lammoglia-Cobo F; Department of Hematology, Oncology and Tumor Immunology, Charite University Hospital Berlin, Berlin, Germany., Remberger M; Department of Medical Sciences, Uppsala University and Clinical Research and Development Unit (KFUE), Uppsala University Hospital, Uppsala, Sweden., Stelljes M; Department of Hematology/Oncology, University Hospital Muenster, Muenster, Germany., Ayuk F; Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany., Zeiser R; Department of Medicine 1, University Hospital Freiburg, Freiburg, Germany., Mackensen A; Department of Medicine 5 Hematology/Oncology, University Hospital Erlangen, Erlangen, Germany.
Publikováno v:
Frontiers in immunology [Front Immunol] 2023 Oct 30; Vol. 14, pp. 1251593. Date of Electronic Publication: 2023 Oct 30 (Print Publication: 2023).
Autor:
Alfaro Moya T; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Mattsson J; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Remberger M; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Lipton JH; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Kim DD; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Viswabandya A; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Kumar R; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Lam W; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Law AD; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Gerbitz A; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Pasic I; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Novitzky-Basso I; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada., Michelis FV; Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada.
Publikováno v:
European journal of haematology [Eur J Haematol] 2023 Oct; Vol. 111 (4), pp. 553-561. Date of Electronic Publication: 2023 Jul 18.
Autor:
Fløisand Y; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. yfl70@me.com., Remberger M; Department of Hematology, Oslo University Hospital, Oslo, Norway.; Clinical Research and Development Unit, Uppsala University Hospital, Uppsala, Sweden., Bigalke I; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Josefsen D; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Vålerhaugen H; Department of Pathology, Oslo University Hospital, Oslo, Norway., Inderberg EM; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Olaussen RW; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway., Gjertsen BT; Department of Clinical Science, University of Bergen; Department of Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway., Goedkoop R; Medigene Immunotherapies GmbH and Medigene AG, Martinsried, Germany., Geiger C; Medigene Immunotherapies GmbH and Medigene AG, Martinsried, Germany., Prinz PU; Medigene Immunotherapies GmbH and Medigene AG, Martinsried, Germany., Schnorfeil FM; Medigene Immunotherapies GmbH and Medigene AG, Martinsried, Germany.; Bavarian Nordic GmbH, Martinsried, Germany., Pinkernell K; Medigene Immunotherapies GmbH and Medigene AG, Martinsried, Germany.; Dr. Falk Pharma, Freiburg, Germany., Schendel DJ; Medigene Immunotherapies GmbH and Medigene AG, Martinsried, Germany., Kvalheim G; Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway.
Publikováno v:
Leukemia [Leukemia] 2023 Sep; Vol. 37 (9), pp. 1842-1849. Date of Electronic Publication: 2023 Jul 28.